Cognition Therapeutics Inc (CGTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.64-7.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CGTX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 27.5 | 37.2 | 41.7 | 37.2 | 30.3 | 18.6 | 12.9 |
| Operating Income | (37.6) | (47.8) | (54.0) | (50.7) | (43.6) | (28.6) | (17.4) |
| Earnings from Continuing Operations | |||||||
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | — |
| Net Income | |||||||
| Net Income | (16.0) | (23.5) | (34.0) | (25.8) | (21.4) | (11.7) | (7.8) |
| Per Share | |||||||
| Basic EPS | (0.17) | (0.32) | (0.86) | (0.86) | (0.91) | (3.13) | (23.76) |
| Diluted EPS | (0.17) | (0.32) | (0.86) | (0.86) | (0.91) | (3.13) | (23.76) |
| Basic Weighted Avg Shares | 95.1 | 72.8 | 39.7 | 30.0 | 23.6 | 5.2 | 0.5 |
| Diluted Weighted Avg Shares | 95.1 | 72.8 | 39.7 | 30.0 | 23.6 | 5.2 | 0.5 |
| Supplemental | |||||||
| EBITDA | — | (47.8) | (53.9) | (50.6) | (43.5) | (28.5) | (17.3) |
| EBIT | (37.6) | (47.8) | (54.0) | (50.7) | (43.6) | (28.6) | (17.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.